Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28: iv1-iv21.
DOI: 10.1093/annonc/mdx222
Majem M, Hernández J, Hernando F, et al. Multidisciplinary consensus statement on the clinical management of patients with stage III non‐small cell lung cancer. Clin Transl Oncol 2020;22:21-36.
DOI: 10.1007/s12094-019-02134-7
Remon J, Soria JC & Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol 2021;32:1637-42.
DOI: 10.1016/j.annonc.2021.08.1994
Spigel DR, Faivre-Finn C, et al. “Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer”. J Clin Oncol 2022;40:1301-11.
DOI: 10.1200/JCO.21.01308
Putora PM, Leskow P, McDonald F, et al. International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? ERJ Open Res 2020;6:00159-02019.
DOI: 10.1183/23120541.00159-2019
Aupérin A, Le Péchoux C, Pignon JP, et al. Meta-Analysis of Cisplatin/carboplatin based Concomitant Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 2006;17:473-83.
DOI: 10.1093/annonc/mdj117
Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-90.
DOI: 10.1200/JCO.2009.26.2543
Daly ME, Singh N, Ismaila N, et al. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol 2022;40:1356-84.
DOI: 10.1200/JCO.21.02528
Liang J, Bi N, Wu S, et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol 2017;28:777-83.
DOI: 10.1093/annonc/mdx009
Senan S, Brade A, Wang LH, et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2016;34:953-62.
DOI: 10.1200/JCO.2015.64.8824
Liu T, He Z, Dang J, et al. Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis. Radiat Oncol 2019;14:55.
DOI: 10.1186/s13014-019-1239-7
Bradley JD, Hu C, Komaki RR, et al. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 2020;38:706-14.
DOI: 10.1200/JCO.19.01162
Kong FM, Hu C, Machtay M, et al. NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC—Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation). J Clin Oncol 2021 39(Suppl.15):8548.
DOI: 10.1200/JCO.2021.39.15_suppl.8548
Mauguen A, Le Péchoux C, Saunders MI, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 2012;30:2788-97.
DOI: 10.1200/JCO.2012.41.6677
Baumann M, Herrmann T, Koch R, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011;100:76-85.
DOI: 10.1016/j.radonc.2011.06.031
Iocolano M, Wild AT, Hannum M, Zhang Z, et al. Hypofractionated frente a. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy. Acta Oncol 2020;59:164-70.
DOI: 10.1080/0284186X.2019.1675907
Robinson SD, Tahir BA, Absalom KAR, et al. Radical accelerated radiotherapy for non-small cell lung cancer (NSCLC): A 5-year retrospective review of two dose fractionation schedules. Radiother Oncol 2020;143:37-43.
DOI: 10.1016/j.radonc.2019.08.025
Nestle U, De Ruysscher D, Ricardi U, et al. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol 2018;127:1-5.
DOI: 10.1016/j.radonc.2018.02.023
De Ruysscher D, Faivre-Finn C, Moeller D, et al; Lung Group and the Radiation Oncology Group of the European Organization for Research and Treatment of Cancer (EORTC). European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol 2017;124:1-10.
DOI: 10.1016/j.radonc.2017.06.003
Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes from the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 2022;40:1301-11.
DOI: 10.1200/JCO.21.01308
AEMPS. Disponible en: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT_1-2020-durvalumab-Imfinzi.pdf?x61259
Herbst RS, Majem M, Barlesi F, Carcereny E, et al. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 2022;40:3383-93.
DOI: 10.1200/JCO.22.00227
Número de descargas:
33720
Número de visitas:
624
Citas:
0
